*U of T, U.K. study focused on Avastin*
Treating ovarian cancer with the drug bevacizumab (“Avastin”) delays the disease and may also improve survival, according to an international clinical trial co-led by Drs. Amit Oza of the University of Toronto and Princess Margaret Hospital (PMH) and Timothy Perren of St James’s Institute of Oncology, Leeds, U.K.
The findings, published on Dec. 28 in the New England Journal of Medicine, report that the drug halted the cancer’s return for two months overall. However, for women with the highest risk disease, the delay was five to six months and in this group, the findings also indicate a strong trend to improved overall survival, which is being analysed until 2013. (more…)